Disclaimer
is resource is for informational purposes only, intended as a quick-reference tool based on the cited source
guideline(s), and should not be used as a substitute for the independent professional judgment of healthcare
providers. Practice guidelines are unable to account for every individual variation among patients or take the
place of clinician judgment, and the ultimate decision concerning the propriety of any course of conduct must
be made by healthcare providers aer consideration of each individual patient situation. Guideline Central
does not endorse any specific guideline(s) or guideline recommendations and has not independently verified the
accuracy hereof. Any use of this resource or any other Guideline Central resources is strictly voluntary.
Source
Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, Chandra V, Drachman DE, Eaves
JM, Ehrman JK, Evans JN, Getchius TS, Gutiérrez JA, Hawkins BM, Hess CN, Ho KJ, Jones WS, Kim
ES, Kinlay S, Kirksey L, Kohlman-Trigoboff D, Long CA, Pollak AW, Sabri SS, Sadwin LB, Secemsky
EA, Serhal M, Shishehbor MH, Treat-Jacobson D, Wilkins LR. 2024 ACC/AHA/AACVPR/APMA/
ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral
artery disease: a report of the American College of Cardiolog y/American Heart Association Joint
Committee on Clinical Practice Guidelines.
[published online ahead of print May 14, 2024]. J Am Coll Cardiol. doi: 10.1016/j.jacc.2024.02.013.
Copublished in Circulation. doi: 10.1161/CIR.0000000000001251.
ACCPAD04243
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2024 All rights reserved
GuidelineCentral.com
Abbreviations
6MWT, 6-minute walk test; AAA, abdominal aortic aneurysm; ABI, ankle-brachial index; ACE,
angiotensin-converting enzyme; AFIB, atrial fibrillation; ALI, acute limb ischemia; APP, Advanced
Practice Provider; ARB, angiotensin-receptor blocker; CAD, coronary artery disease; CKD, chronic
kidney disease; CLTI, chronic limb-threatening ischemia; COMPASS, Cardiovascular Outcomes
for People Using Anticoagulation Strategies; COVID-19, coronavirus disease 2019; CTA, computed
tomography angiography; CVD, cardiovascular disease; ESKD, end-stage kidney disease; EUCLID,
Examining Use of Ticagrelor in Peripheral Artery Disease; FDA, US Food and Drug Administration;
GDMT, guideline-directed management and therapy; GLASS, Global Limb Anatomic Staging
System; GNRI, Geriatric Nutritional Risk Index; HR, hazard ratio; ICD, International Classification
of Diseases; LDL-C, low-density lipoprotein-cholesterol; MACE, major adverse cardiovascular events;
MALE, major adverse limb events; MI, myocardial infarction; MRA, magnetic resonance angiography;
NPWT, negative pressure wound therapy; OR, odds ratio; PAD, peripheral artery disease; PTA,
percutaneous transluminal angioplasty; PVR, pulse volume recording ; QOL, quality of life; RCT,
randomized controlled trial; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SBP,
systolic blood pressure; SET, supervised exercise therapy; SGLT-2, sodium-glucose cotransporter-2;
SPP, skin perfusion pressure; TBI, toe-brachial index; TcPO
2
, transcutaneous oxygen pressure; VA, US
Department of Veterans Affairs; VOYAGER PAD, Vascular Outcomes Study of ASA (acetylsalicylic
acid) Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD; WIf I,
wound, ischemia, and foot infection
